Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) — Strategic Asset Allocation Index
Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) has a Strategic Asset Allocation Index of 122.0% as of June 2023. Strategic assets (PP&E of CN¥8.76 Billion plus long-term investments of CN¥-) total CN¥8.76 Billion, measured against net assets of CN¥7.18 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Starlake Bioscience Co Inc Zhaoqing Guangdong Strategic Asset Allocation Index (2000–2022)
This chart shows how Starlake Bioscience Co Inc Zhaoqing Guangdong's Strategic Asset Allocation Index has evolved across 23 annual periods from 2000 to 2022. As of June 2023, the index stands at 122.0%, representing strategic assets of CN¥8.76 Billion against net assets of CN¥7.18 Billion CNY. Explore Starlake Bioscience Co Inc Zhaoqing Guan operating cash flow efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Starlake Bioscience Co Inc Zhaoqing Guangdong (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Starlake Bioscience Co Inc Zhaoqing Guangdong from 2000 to 2022, covering 23 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Starlake Bioscience Co Inc Zhaoqing Guan (600866) market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 129.8% | CN¥9.00 Billion | CN¥9.00 Billion | CN¥- | CN¥6.93 Billion | ▲ +57.5 pp |
| 2021 | 72.3% | CN¥1.28 Billion | CN¥1.28 Billion | CN¥- | CN¥1.78 Billion | ▼ -4.1 pp |
| 2020 | 76.4% | CN¥1.28 Billion | CN¥1.28 Billion | CN¥- | CN¥1.67 Billion | ▲ +12.7 pp |
| 2019 | 63.7% | CN¥968.92 Million | CN¥929.92 Million | CN¥38.99 Million | CN¥1.52 Billion | ▼ -21.7 pp |
| 2018 | 85.5% | CN¥817.44 Million | CN¥778.45 Million | CN¥38.99 Million | CN¥956.42 Million | ▼ -4.1 pp |
| 2017 | 89.6% | CN¥819.21 Million | CN¥780.21 Million | CN¥38.99 Million | CN¥914.14 Million | ▲ +13.9 pp |
| 2016 | 75.7% | CN¥812.34 Million | CN¥773.34 Million | CN¥38.99 Million | CN¥1.07 Billion | ▼ -9.3 pp |
| 2015 | 85.1% | CN¥891.90 Million | CN¥852.90 Million | CN¥38.99 Million | CN¥1.05 Billion | ▲ +16.9 pp |
| 2014 | 68.2% | CN¥1.00 Billion | CN¥1.00 Billion | CN¥- | CN¥1.47 Billion | ▼ -25.6 pp |
| 2013 | 93.7% | CN¥1.37 Billion | CN¥1.37 Billion | CN¥- | CN¥1.47 Billion | ▼ -40.4 pp |
| 2012 | 134.1% | CN¥2.19 Billion | CN¥2.19 Billion | CN¥- | CN¥1.63 Billion | ▲ +34.2 pp |
| 2011 | 100.0% | CN¥1.80 Billion | CN¥1.80 Billion | CN¥- | CN¥1.80 Billion | ▲ +56.4 pp |
| 2010 | 43.6% | CN¥701.17 Million | CN¥701.17 Million | CN¥- | CN¥1.61 Billion | ▼ -27.3 pp |
| 2009 | 70.8% | CN¥722.61 Million | CN¥722.61 Million | CN¥- | CN¥1.02 Billion | ▼ -31.0 pp |
| 2008 | 101.8% | CN¥790.69 Million | CN¥790.69 Million | CN¥- | CN¥776.46 Million | ▼ -4.8 pp |
| 2007 | 106.6% | CN¥791.24 Million | CN¥791.24 Million | CN¥- | CN¥742.02 Million | ▲ +11.5 pp |
| 2006 | 95.1% | CN¥848.73 Million | CN¥848.73 Million | CN¥- | CN¥892.18 Million | ▼ -0.5 pp |
| 2005 | 95.7% | CN¥837.00 Million | CN¥837.00 Million | CN¥- | CN¥874.86 Million | ▲ +21.8 pp |
| 2004 | 73.8% | CN¥659.65 Million | CN¥659.65 Million | CN¥- | CN¥893.38 Million | ▲ +25.8 pp |
| 2003 | 48.0% | CN¥434.39 Million | CN¥434.39 Million | CN¥- | CN¥904.58 Million | ▼ -3.3 pp |
| 2002 | 51.3% | CN¥428.29 Million | CN¥428.29 Million | CN¥- | CN¥834.94 Million | ▲ +1.6 pp |
| 2001 | 49.7% | CN¥375.68 Million | CN¥375.68 Million | CN¥- | CN¥755.58 Million | ▲ +3.9 pp |
| 2000 | 45.8% | CN¥344.04 Million | CN¥344.04 Million | CN¥- | CN¥751.40 Million | — |